FDA Drug Enforcement Actions

HEHS-94-136R: Published: May 6, 1994. Publicly Released: May 6, 1994.

Additional Materials:

Contact:

Office of Public Affairs
(202) 512-4800
youngc1@gao.gov

Pursuant to a congressional request, GAO reviewed the Food and Drug Administration's (FDA) monitoring of generic drug manufacturers, focusing on whether: (1) policies and procedures exist to ensure that manufacturers produce safe and effective products; (2) FDA is pursuing enforcement actions against manufacturers; and (3) manufacturing companies are aware of FDA standards for assessing their compliance with good manufacturing practices (GMP). GAO noted that: (1) FDA districts have discretion in dealing with manufacturers and training their investigators; (2) FDA lacks assurance that districts select and inspect manufacturers fairly and that districts forward recommendations for enforcement action to FDA headquarters; (3) FDA is developing certification criteria for drug investigators, since decentralized training does not ensure consistent inspections; (4) despite the potential for inconsistent inspections, there have been no inappropriate FDA inspection and enforcement actions; and (5) manufacturers are generally aware of the standards that FDA uses to determine GMP compliance.

Sep 26, 2018

Sep 5, 2018

Jul 18, 2018

Jul 16, 2018

Jun 27, 2018

May 31, 2018

May 17, 2018

Apr 18, 2018

Apr 12, 2018

Looking for more? Browse all our products here